EGFR mutations and lung cancer

G da Cunha Santos, FA Shepherd… - Annual Review of …, 2011 - annualreviews.org
Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic
kinase activity that transduces important growth factor signaling from the extracellular milieu …

[HTML][HTML] Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy

G Pines, WJ Köstler, Y Yarden - FEBS letters, 2010 - Elsevier
The EGF-receptor is frequently mutated in a large variety of tumors. Here we review the most
frequent mutations and conclude that they commonly enhance the intrinsic tyrosine kinase …

[HTML][HTML] Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT …

M Beau-Faller, N Prim, AM Ruppert, I Nanni-Metéllus… - Annals of oncology, 2014 - Elsevier
Background There is scarce data available about epidermal growth factor receptor (EGFR)
mutations other than common exon 19 deletions and exon 21 (L858R) mutations. Patients …

[HTML][HTML] Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations

CH Chiu, CT Yang, JY Shih, MS Huang, WC Su… - Journal of thoracic …, 2015 - Elsevier
Background Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …

[HTML][HTML] Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors

S Kobayashi, HM Canepa, AS Bailey… - Journal of Thoracic …, 2013 - Elsevier
Background: Non–small-cell lung cancers (NSCLCs) containing EGFR mutations are
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the …

T John, G Liu, MS Tsao - Oncogene, 2009 - nature.com
Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease.
Current treatment paradigms are shifting from cytotoxic chemotherapies alone to single …

Cancer genes in lung cancer: racial disparities: are there any?

A El-Telbany, PC Ma - Genes & cancer, 2012 - journals.sagepub.com
Cancer is now known as a disease of genomic alterations. Mutational analysis and
genomics profiling in recent years have advanced the field of lung cancer …

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC

A Kalikaki, A Koutsopoulos, M Trypaki… - British journal of …, 2008 - nature.com
In non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) and K-RAS
mutations of the primary tumour are associated with responsiveness and resistance to …

Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non–small cell lung cancer cell line

A Ogino, H Kitao, S Hirano, A Uchida, M Ishiai… - Cancer research, 2007 - AACR
The epidermal growth factor receptor (EGFR)–specific tyrosine kinase inhibitor gefitinib may
provide dramatic clinical responses in some patients with pulmonary adenocarcinoma …

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution

K Li, M Yang, N Liang, S Li - Oncology reports, 2017 - spandidos-publications.com
Mutations in epidermal growth factor receptor (EGFR) play critical roles in the pathogenesis
of non-small cell lung cancer (NSCLC), and they are highly associated with sensitivity to …